

<b>INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e)</b>  Address to: Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	SEEK-001CON
	First Named Inventor	BERG, ELLEN L.
	Application Number	10/716,349
	Confirmation No.	7039
	Filing Date	November 17, 2003
	Group Art Unit	1645
	Examiner Name	
Title: "FUNCTION HOMOLOGY SCREENING"		

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. SEEK-001CON.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: October 18, 2005

BOZICEVIC, FIELD & FRANCIS LLP  
1900 University Avenue, Suite 200  
East Palo Alto, California 94303  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

By: Pamela J. Sherwood  
Pamela J. Sherwood, Reg. No. 36,677

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/716,349
		Filing Date	November 17, 2003
		First Named Inventor	BERG, ELLEN L.
		Art Unit	1645
Examiner Name			
Attorney Docket Number	SEEK-001CON		
Sheet	1	of	1

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 96/23075	08-01-1996	BOGGS		
		WO 95/06132	03-02-1995	ANDRIANOPOULOS		

NON PATENT LITERATURE DOCUMENTS			
Exam iner Initial	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		MAY et al., EFFECTS OF PROTEIN TYROSINE KINASE INHIBITORS ON CYTOKINE-INDUCED ADHESION MOLECULE EXPRESSION BY HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS, Brit. Journal, of Pharmacology, 1996, 118(7): 1761-1771	
		RICE et al., DEVELOPMENT OF A HIGH VOLUME SCREEN TO IDENTIFY INHIBITORS OF ENDOTHELIAL CELL ACTIVATION, Analytical Biochem., 1996, 241(2): 254-259	
		HAUSNER et al., THE COMPARATIVE GROWTH ASSAY: EXAMINING THE INTERPLAY OF ANTI-CANCER AGENTS WITH CELLS CARRYING SINGLE GENE ALTERATIONS, Neoplasia, Doyle, 1999, 1(4): 356-367	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.